Search results for "radioprotectors"

showing 1 items of 1 documents

Radioprotection and Radiomitigation: From the Bench to Clinical Practice.

2020

The development of protective agents against harmful radiations has been a subject of investigation for decades. However, effective (ideal) radioprotectors and radiomitigators remain an unsolved problem. Because ionizing radiation-induced cellular damage is primarily attributed to free radicals, radical scavengers are promising as potential radioprotectors. Early development of such agents focused on thiol synthetic compounds, e.g., amifostine (2-(3-aminopropylamino) ethylsulfanylphosphonic acid), approved as a radioprotector by the Food and Drug Administration (FDA, USA) but for limited clinical indications and not for nonclinical uses. To date, no new chemical entity has been approved by …

0301 basic medicineMedicine (miscellaneous)free radicalsReviewPharmacologyFilgrastimGeneral Biochemistry Genetics and Molecular BiologyIonizing radiation03 medical and health sciences0302 clinical medicineSargramostimNew chemical entitymedicinelcsh:QH301-705.5business.industryradioprotectorsAcute Radiation SyndromeAmifostine030104 developmental biologyantioxidantslcsh:Biology (General)Protective Agents030220 oncology & carcinogenesisradiomitigatorsionizing radiationsbusinessPegfilgrastimmedicine.drugBiomedicines
researchProduct